No.30 Science Park Road
Zhong-Guan-Cun Life Science Park
About BeiGene Co.,LtdBeiGene is a globally focused biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.
October 28, 2010
Founders: Xiaodong Wang, and John Oyler
CEO: John Oyler
CFO: Howard Liang
CMO (Medical): Eric Hedrick
Please click here for BeiGene job opportunities.
Please click here for clinical trial information.
350 articles with BeiGene Co.,Ltd
Capping off the first half of the year is a flurry of clinical trial wins. BioSpace takes a look at some of the most exciting ones:
BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma
BeiGene announced new data from RATIONALE 306, a global Phase 3 trial evaluating tislelizumab plus chemotherapy in adult patients with advanced or metastatic esophageal squamous cell carcinoma without prior systemic treatment for advanced disease.
Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma
Antengene Corporation Limited announced that it has entered into a clinical trial collaboration with BeiGene to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of selinexor in combination with BeiGene's anti-PD-1 checkpoint inhibitor, tislelizumab.
BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab
Submission seeks marketing authorization for use with chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma whose tumor expresses PD-L1.
BeiGene Announces BRUKINSA ™ (zanubrutinib) Is Approved in 50 Markets.
Following Additional Data Submission to FDA Demonstrating ORR Superiority Over Ibrutinib As Determined by IRC, PDUFA Goal Date Extended to January 20, 2023 to Allow Time for Review.
Tislelizumab is now approved in nine indications in China.
BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress
Clinical data and patient-reported outcomes across extensive clinical development program for zanubrutinib (BRUKINSA ® ) reinforce its potential across B-cell malignancies.
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that Julia Wang, Chief Financial Officer, and Angus Grant, Ph.D., Chief Business Executive, will participate in a fireside chat at the Goldman Sachs Conference.
Zymeworks increased its stake in the company to 6.9%, slightly under 4 million shares, and options with shares popped 13% after the original bid and are up another 10%.
BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and Growing Oncology Portfolio
BeiGene will present data from its broad solid tumor and hematology portfolios in eight presentations at the upcoming American Society of Cancer Oncology Annual Meeting being held in Chicago from June 3-7, 2022.
BeiGene, Ltd., a global biotechnology company focused on developing and commercializing innovative medicines worldwide, yesterday announced the opening of a new regional office in Basel, Switzerland.
Genentech's flop of its anti-TIGIT drug has cast a shadow of doubt over the numerous companies in the process of developing their own anti-TIGIT drugs.
BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced 20 presentations from the Company’s global clinical development programs in hematologic malignancies at the European Hematology Association (EHA) 2022 Hybrid Congress.
The U.S. SEC continues to tighten the screws on Chinese companies, adding more than 80 companies to its expanding list of companies that might be dropped from U.S. stock exchanges.
Despite a growing product revenue, Beigene reported a net loss of $434.4 million for the first quarter of 2022, as well as updates to its audit from the SEC.
BeiGene, Ltd. today reported financial results for the first quarter of 2022, recent business highlights, and anticipated upcoming milestones.
BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
BeiGene announced that the China National Medical Products Administration has granted conditional approval of BLINCYTO® for injection for the treatment of pediatric patients with relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia.
BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton West Innovation Campus in New Jersey
BeiGene, Ltd. announced the groundbreaking of its flagship U.S. manufacturing and clinical R&D center at the Princeton West Innovation Campus in Hopewell, N.J.
Zymeworks received an unsolicited, non-binding acquisition offer from global investment firm All Blue Capital. All Blue is offering $10.50 per share for a total of $773 million in cash.